What is the recommended method for adjusting carbimazole dosage in patients with hyperthyroidism?

Carbimazole Dose Adjustment in Hyperthyroidism

Start carbimazole at 15–40 mg once daily based on disease severity, measure free T4 and total T3 at week 4, then titrate the dose downward every 4–8 weeks until euthyroidism is achieved on the minimal effective maintenance dose (typically 5–10 mg daily), continuing therapy for 12–18 months total. 1

Initial Dosing Strategy

Dose selection depends on baseline hyperthyroidism severity:

• Mild hyperthyroidism (free T4 < 3× upper limit of normal): start 15–20 mg carbimazole once daily 1
• Moderate-to-severe hyperthyroidism (free T4 ≥ 3× upper limit of normal): start 30–40 mg carbimazole once daily 1
• Once-daily dosing is appropriate because carbimazole's active metabolite (methimazole) has a long intrathyroidal half-life 1
• The goal is to achieve euthyroidism within approximately 4 weeks 1

Dose equivalence: 10 mg carbimazole = 6 mg methimazole 1

Monitoring Schedule and Dose Titration Algorithm

Week 4 assessment:

• Measure free T4 and total T3 (TSH remains unreliable at this stage because it stays suppressed for weeks to months) 1
• If free T4 has normalized or fallen to low-normal range, reduce carbimazole by 50% (e.g., from 30 mg to 15 mg daily) 1, 2
• If free T4 remains elevated but has decreased substantially, continue the current dose and recheck in 4 weeks 1
• If free T4 shows minimal response, verify adherence and consider increasing the dose 1

Weeks 8–12 and beyond:

• Repeat thyroid function tests every 4–8 weeks until euthyroid on the minimal effective dose 1
• Once euthyroidism is achieved, continue monitoring every 2–3 months for the remainder of the 12–18 month course 1
• Target free T4 at or slightly above the upper limit of normal while TSH remains suppressed; this is expected and does not indicate treatment failure 1

Maintenance phase:

• Typical maintenance dose is 5–10 mg carbimazole daily (equivalent to 3–6 mg methimazole) 1
• Continue this dose for the full 12–18 months to maximize remission chance 3, 1

Special Populations Requiring Modified Dosing

Patients with small thyroid glands and markedly elevated TSH-receptor antibodies:

• These patients are "dose-sensitive" and may become hypothyroid on conventional doses 4
• Consider starting at the lower end of the dosing range (15 mg daily) and monitoring more frequently (every 2–3 weeks initially) 4
• Fine-tune with smaller dose adjustments (2.5–5 mg increments) 4

Patients under age 30:

• Younger patients respond less rapidly to carbimazole; 50% remain biochemically hyperthyroid after 4–6 weeks on 40 mg daily, compared to only 14% of patients over 30 5
• Consider starting at the higher end of the dosing range (40 mg daily) in young adults with moderate-to-severe disease 5

Pediatric patients:

• First-line treatment is methimazole/carbimazole for 3 years or more (longer than adults) 6
• Use dose titration rather than block-and-replace regimens 6

Pregnancy:

• First trimester: switch immediately to propylthiouracil because carbimazole/methimazole causes congenital malformations 1, 7
• Second and third trimesters: switch back to carbimazole/methimazole to avoid propylthiouracil hepatotoxicity 1, 7
• Monitor thyroid function monthly and adjust dose to keep free T4 at or slightly above the upper limit of the non-pregnant reference range 1

Critical Pitfalls to Avoid

Do not stop therapy at 14 weeks when aiming for medical remission:

• A 14-week course is only appropriate if definitive therapy (radioactive iodine or thyroidectomy) is planned 1
• Stopping at 14 weeks when the goal is remission virtually guarantees relapse 1

Do not rely on TSH for dose adjustment in the first 3 months:

• TSH remains suppressed for 1–3 months after free T4 normalizes 1
• Use free T4 and total T3 as primary parameters for dose titration during this period 1

Do not perform routine white blood cell monitoring:

• Agranulocytosis develops rapidly; >60% of affected patients have normal counts within 2 weeks of symptom onset 1
• Obtain a differential white blood cell count only during febrile illness or pharyngitis 3, 1

Do not switch to propylthiouracil except in first-trimester pregnancy or thyroid storm:

• Propylthiouracil carries higher hepatotoxicity risk, including fatal hepatic necrosis 1, 8
• Cross-reactivity between carbimazole and propylthiouracil is absolute in agranulocytosis; switching is contraindicated 9

Do not aim for normal TSH during active treatment:

• Persistent TSH suppression while free T4 is normal does not reflect treatment failure 1
• Attempting to normalize TSH risks iatrogenic hypothyroidism, which can worsen Graves' orbitopathy 1

Patient Safety Instructions

Instruct all patients to stop carbimazole immediately and contact you if they develop: 3, 1

• Fever or sore throat (agranulocytosis)
• Jaundice, dark urine, or pale stools (hepatotoxicity)
• Severe abdominal pain or persistent nausea
• Pruritic rash or arthralgias

Baseline laboratory studies before starting therapy: 3, 1

• Complete blood count with differential
• Liver function tests (bilirubin, ALT, AST, alkaline phosphatase)

Do not perform routine follow-up CBC or liver function tests unless symptoms develop 3, 1

End-of-Treatment Decision Making

At 12–18 months:

• Measure TSH-receptor antibodies before stopping therapy 3, 1
• Elevated antibodies predict ≥50% relapse risk; consider continuing low-dose carbimazole or definitive therapy 3, 1
• If TSH is normal and antibodies are low/negative, taper or discontinue carbimazole 3, 1

After discontinuation:

• Monitor TSH and free T4 every 1–3 months for 6–12 months to detect early relapse 1
• Overall relapse rate after short-term therapy is approximately 50% 1

If relapse occurs:

• Offer radioactive iodine or thyroidectomy as first-line options 3, 1
• Long-term low-dose carbimazole (5–10 years) is an alternative for patients who decline definitive therapy, with a 15% recurrence rate versus 50% after short-term therapy 1